Ndubaku Chudi O, Crawford James J, Drobnick Joy, Aliagas Ignacio, Campbell David, Dong Ping, Dornan Laura M, Duron Sergio, Epler Jennifer, Gazzard Lewis, Heise Christopher E, Hoeflich Klaus P, Jakubiak Diana, La Hank, Lee Wendy, Lin Baiwei, Lyssikatos Joseph P, Maksimoska Jasna, Marmorstein Ronen, Murray Lesley J, O'Brien Thomas, Oh Angela, Ramaswamy Sreemathy, Wang Weiru, Zhao Xianrui, Zhong Yu, Blackwood Elizabeth, Rudolph Joachim
Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States.
Afraxis, Inc. , 6605 Nancy Ridge Road, Suite 224, San Diego, California 92121, United States.
ACS Med Chem Lett. 2015 Oct 31;6(12):1241-6. doi: 10.1021/acsmedchemlett.5b00398. eCollection 2015 Dec 10.
Signaling pathways intersecting with the p21-activated kinases (PAKs) play important roles in tumorigenesis and cancer progression. By recognizing that the limitations of FRAX1036 (1) were chiefly associated with the highly basic amine it contained, we devised a mitigation strategy to address several issues such as hERG activity. The 5-amino-1,3-dioxanyl moiety was identified as an effective means of reducing pK a and logP simultaneously. When positioned properly within the scaffold, this group conferred several benefits including potency, pharmacokinetics, and selectivity. Mouse xenograft PK/PD studies were carried out using an advanced compound, G-5555 (12), derived from this approach. These studies concluded that dose-dependent pathway modulation was achievable and paves the way for further in vivo investigations of PAK1 function in cancer and other diseases.
与p21激活激酶(PAK)相互作用的信号通路在肿瘤发生和癌症进展中起重要作用。通过认识到FRAX1036(1)的局限性主要与其所含的高碱性胺有关,我们设计了一种缓解策略来解决诸如hERG活性等几个问题。5-氨基-1,3-二氧戊环部分被确定为同时降低pKa和logP的有效手段。当该基团在支架中正确定位时,赋予了多种益处,包括效力、药代动力学和选择性。使用源自该方法的先进化合物G-5555(12)进行了小鼠异种移植PK/PD研究。这些研究得出结论,剂量依赖性途径调节是可行的,为进一步在体内研究PAK1在癌症和其他疾病中的功能铺平了道路。